Zenrelia Tabs

Ilunocitinib (JAK inhibitor) for atopic dermatitis and pruritus in dogs; daily oral administration. JAK inhibitor (ilunocitinib). Mechanism: selectively inhibits JAK1 → blocks interleukin signaling (IL-4, IL-13, IL-31, TSLP) → reduces T-helper 2 (Th2)-driven atopic inflammation and pruritus. Oral once-daily tablet. More selective JAK1 inhibitor profile than oclacitinib. For canine atopic dermatitis. Key information Ziltivekimab — IL-31 antibody for canine pruritus. Refrigerate; do not freeze. Subcutaneous injection. Monthly dosing. Dogs only.

Oral tablets: Administer orally. May be given with food to improve compliance and reduce GI upset. Administer with food to reduce GI adverse effects. Administer once daily at consistent time. Store at room temperature; protect from light. If a dose is missed This product is given as a single dose or as part of a defined protocol. Contact your veterinarian if a scheduled administration was missed. Zenrelia is given monthly — contact your veterinarian to reschedule.

GI: vomiting, diarrhea, decreased appetite. CNS: sedation (uncommon). Increased susceptibility to infections (JAK1 inhibition). Anemia (rare). Generally well tolerated. More selective JAK1 profile than oclacitinib — developing safety profile.

For animals Avoid in dogs with active serious infections. Pre-existing neoplasia: use with caution. Monitor for infections. Avoid in pregnant animals. Not approved for use in food-producing animals. For people handling this medication Wash hands thoroughly with soap and water after handling. Avoid contact with eyes; if contact occurs, flush with water for 15 minutes and seek medical attention. Keep out of reach of children. If accidental ingestion occurs, contact Poison Control (1-800-222-1222). JAK inhibitor — Wash hands thoroughly with soap and water after handling. after handling. Keep out of reach of children. Pregnant women and women of childbearing age should avoid contact.

Contact your veterinarian. Monoclonal antibody overdose — contact vet for guidance.